1. Phase II study of liposomal doxorubicin in refractory ovarian cancer;Muggia;J. Clin. Oncol.,1997
2. Rose P, Gordon AN, Granai CO, et al. Interim analysis of a non-comparative multicenter study of Doxil/Caelyx in the treatment of patients with refractory ovarian cancer. Proc Am Soc Clin Oncol 1999, 18, 360a (abstr 1392).
3. Hensley M, Hoppe B, Leon L, et al. Clinical use of liposomal doxorubicin in platinum-refractory ovarian cancer: predictors of response in pre-treated patients. Proc Am Soc Clin Oncol 2000, 19, 393a (abstr 1555).
4. Campos SM, Penson RT, MacNeill KM, et al. A retrospective analysis of the clinical utility of Doxil in recurrent ovarian cancer. J Clin Oncol 1999, 18, 371a (abstr 1434).
5. Gordon AN, Fleagle JT, Guthrie D, Parkin, Gore ME. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 2001, 19 (in press).